Harvard Bioscience (HBIO) Gross Profit (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Gross Profit data on file, last reported at $12.2 million in Q1 2026.

• Gross Profit for Q1 2026 came in at $12.2 million, changed 0.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $50.0 million (down 4.23% YoY), and the FY2025 annual result was $49.9 million, down 8.87% from the prior year.
• Gross Profit declined to $12.2 million in Q1 2026 per HBIO's latest filing, from $14.2 million in the prior quarter.
• Over five years, Gross Profit peaked at $18.3 million in Q1 2023 and troughed at $11.5 million in Q2 2025.
• A 5-year average of $14.3 million and a median of $14.2 million in 2025 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2022 and 2023: Gross Profit slipped 25.36% in 2022, then advanced 20.99% in 2023.
• A 5-year view of Gross Profit shows it stood at $15.8 million in 2022, then increased by 3.11% to $16.3 million in 2023, then retreated by 14.17% to $14.0 million in 2024, then climbed by 1.15% to $14.2 million in 2025, then declined by 13.6% to $12.2 million in 2026.
• Business Quant data shows HBIO's Gross Profit at $12.2 million in Q1 2026, $14.2 million in Q4 2025, and $12.0 million in Q3 2025.